Adverum Biotechnologies

Adverum, formerly Avalanche Biotechnologies, is a biotechnology company developing gene therapies for patients living with rare diseases and diseases of the eye that is headquartered in Menlo Park, California and was founded in 2006 by Mark S. Blumenkranz, Mitchell H. Finer, Steven D. Schwartz, and Thomas W. Chalberg. The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investors.

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.